Top
image credit: svstudioart / Freepik

Swiss Re on the role of genomics in the insurance industry

June 26, 2024

The emergence of genomics, the study of genes and its arrangements and interactions, has a role insurers should be taking note of, a recently released report by Swiss Re found.

The report entitled “Genomics: Litigation Risks and Rewards,” suggests genomic bears relevance in claims and litigation for personalized medicine and healthcare as well as personal injury and mass tort litigation as genomic evidence has been used in several cases concerning claims.

The report detailed how insurers who are concerned with healthcare and physician medical malpractice ought to appreciate the use of testing as well as the expertise in understanding and communicating results, commitment to emerging guidelines, and protocol consistency.

Read More on Insurance Business